Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Cytokinetics Inc., consolidated income statement

US$ in thousands

12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Research and development revenues	6,588)	10,572)	16,527)	26,868)	26,368)
License revenues	—)	54,856)	36,501)	—)	5,133)
Milestone revenues	1,000)	5,000)	2,800)	—)	—)
Realization of revenue participation right purchase agreement	87,000)	—)	—)	—)	—)
Revenues	94,588)	70,428)	55,828)	26,868)	31,501)
Research and development	(240,813)	(159,938)	(96,951)	(86,125)	(89,135)
General and administrative	(177,977)	(96,803)	(52,820)	(39,610)	(31,282)
Operating expenses	(418,790)	(256,741)	(149,771)	(125,735)	(120,417)
Operating loss	(324,202)	(186,313)	(93,943)	(98,867)	(88,916)
Interest expense	(19,414)	(16,440)	(15,963)	(6,623)	(3,797)
Loss on settlement of debt	(24,939)	—)	—)	—)	—)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(31,742)	(12,892)	(22,713)	(20,737)	(17,767)
Interest and other income, net	11,342)	331)	5,329)	4,535)	4,191)
Loss, before income tax provision	(388,955)	(215,314)	(127,290)	(121,692)	(106,289)
Income tax provision	—)	—)	—)	—)	—)
Net loss	(388,955)	(215,314)	(127,290)	(121,692)	(106,289)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Download chart

Income statement item	Description	The company
Revenues	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Cytokinetics Inc. revenues increased from 2020 to 2021 and from 2021 to 2022.
Operating loss	The net result for the period of deducting operating expenses from operating revenues.	Cytokinetics Inc. operating loss decreased from 2020 to 2021 and from 2021 to 2022.
Loss, before income tax provision	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Cytokinetics Inc. loss, before income tax provision decreased from 2020 to 2021 and from 2021 to 2022.
Net loss	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Cytokinetics Inc. net loss decreased from 2020 to 2021 and from 2021 to 2022.

Cytokinetics Inc. (NASDAQ:CYTK)

Income Statement